- Home
- MDGL vs TFX Comparison
MDGL vs TFX Comparison
Compare MDGL & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | TFX |
|---|---|---|
| Founded | 2011 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 4.6B |
| IPO Year | 2005 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MDGL | TFX |
|---|---|---|
| Price | $449.10 | $106.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 8 |
| Target Price | ★ $674.45 | $140.29 |
| AVG Volume (30 Days) | 268.7K | ★ 783.4K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.29% |
| EPS Growth | ★ 41.32 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $180,133,000.00 | ★ $1,992,713,000.00 |
| Revenue This Year | $58.28 | $46.78 |
| Revenue Next Year | $46.80 | $3.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $265.00 | $100.18 |
| 52 Week High | $615.00 | $142.96 |
Technical Indicators
Market Signals| Indicator | MDGL | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 40.28 |
| Support Level | $416.43 | $102.03 |
| Resistance Level | $463.63 | $108.01 |
| Average True Range (ATR) | 16.53 | 2.92 |
| MACD | 3.97 | -1.04 |
| Stochastic Oscillator | 60.74 | 8.12 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.